trending Market Intelligence /marketintelligence/en/news-insights/trending/g88f7dtt5qkp4716kt6rza2 content esgSubNav
In This List

TrovaGene to undertake 1-for-12 reverse stock split

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


TrovaGene to undertake 1-for-12 reverse stock split

TrovaGene Inc. said it will undertake a 1-for-12 reverse split of its common stock.

The San Diego-based oncology therapeutics company said its stock will begin trading on the Nasdaq Capital Market on a split-adjusted basis when the markets open June 4.

The company's outstanding common shares will be reduced to 4.9 million shares from 59.4 million shares following the stock split.

The reverse stock split has the approval of the company's board and a majority of its shareholders.